CorTec and the EIC Accelerator: A Brain Implant for Stroke

CorTec, a Freiburg neurotechnology company led by CEO Frank Desiere, makes the Brain Interchange, a fully implanted system that records brain activity and delivers electrical stimulation to the cortex in a closed loop. Its EIC project promised to "finalise the development of our tech for stroke rehabilitation, conduct clinical trials & get market approval in 2029, generating €250M in sales in 2030", according to CORDIS.

The European Innovation Council granted €2,500,000 towards a €3.68 million project from November 2022 to October 2024. The final report lists implantable connectors, stiffer electrodes for burr-hole surgery, a more stable wireless link, a stronger hermetic package, a data cloud and encryption, and a 30% cut in power use to keep the implant cool. It also records an unsolved problem: in a 3 tesla MRI scanner, the implant's magnet casts a shadow of about 50 mm radius, "compromising the diagnostic purpose of MRI head scans". In July 2025 the first stroke patient was implanted in Seattle, and by April 2026 a third, CorTec said.

Where CorTec Stands Now

In April 2026 the US Food and Drug Administration granted Brain Interchange a Breakthrough Device Designation for stroke motor rehabilitation and accepted it into its Total Product Life Cycle Advisory Program. A second designation followed in August 2026 for cursor control by people with quadriplegia, after a stroke study participant controlled a computer with the implant, according to CorTec. The US trial is funded by the National Institutes of Health. CorTec filed its 2024 accounts with an earnings statement in January 2026 and continues to file patents, North Data shows.

The Technology: Stimulating the Brain in Time With Itself

After a stroke, rehabilitation depends on the brain's ability to rewire itself. CorTec's implant senses brain signals, sends them wirelessly to a computer that decides when to stimulate, and then stimulates the cortex, with the aim of boosting neuroplasticity during therapy. The report says a first use in two epilepsy patients showed the system could stimulate locked to the brain's beta rhythm without being disturbed by its own stimulation artefacts.

What the EIC Project Promised, and What CORDIS Shows

The grant was to finalise the system so that a pivotal trial could follow. The report documents extensive engineering progress but leaves open the MRI shadowing problem and notes that an outside cybersecurity review made recommendations for the final product. The clinical study under way gathers initial safety data in three patients; it is not a pivotal trial. CORDIS lists the project as closed.

1. Implant hardeningDeliveredConnectors, package, power.
2. MRI compatibilityPartial50 mm image shadow.
3. Stroke clinical useStarted3 patients, 2025-26.
4. Pivotal trialNot startedFeasibility stage.

The Money

The Strüngmann family's Santo Venture Capital invested €13 million in 2019, alongside earlier backers LBBW Venture Capital and High-Tech Gründerfonds. CorTec's revenue and losses are filed but not publicly summarised. Whether the EIC Fund invested under the blended award is not public.

What Cannot Be Checked

Why Europe Should Care

Brain-computer interfaces are a field CorTec's CEO calls "dominated by U.S. players". CorTec says it develops and manufactures its implant entirely in Germany, and the EIC paid for a large part of its final development. Its first human stroke trial, however, is in the United States with US federal money.

The Verdict

CorTec and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.